Jan 26, 2024
PulseMedica aims to transform vitreoretinal disease outcomes in the blink of an eye.
Inside a nondescript office building in downtown Edmonton is an image-guided therapy company hard at work building revolutionary technology that has the potential to significantly impact eye imaging and treatment. PulseMedica, founded in 2020 by Dr. Abdul Elezzabi, Dr. Nir Katchinskiy, and Eric Martin, is poised to revolutionize how many common vitreoretinal eye diseases, like diabetic retinopathy and eye floaters, are identified, monitored, and treated.
From the instant you walk into PulseMedica’s office, you’re transported to a vibrant and buzzing open concept office-lab, designed to support their multi-disciplinary engineers to collaborate and build synchronously in real-time. Its office is no different from a beehive, with each person intensely focused on their work to build this groundbreaking medical innovation. From the whirring of machines and brainstorming chatter, you’re instantly pulled into the excitement of an eager team. With its growing team, PulseMedica is rapidly preparing to launch its image-guided therapy prototype device into the clinic in the coming months to complete their clinical trials.
The PulseMedica platform is a 3D image-guided therapy device that integrates powerful laser therapy, advanced medical imaging, and limitless machine learning (ML) for precision imaging and treatment of vitreoretinal disease. Vitreoretinal diseases exist within the clear gel (vitreous fluid) that fills the eye and retina at the back of the eye. PulseMedica’s device strives to automate the imaging and treatment process, enabling quick and precise disease targeting, thereby reducing the treatment time and reducing the risk of side effects and total time per patient, allowing for more patients to be treated each day.
An electrical engineer by training, Katchinskiy’s and Elezzabi’s vision for their device began with the Femtosecond laser research and development at the University of Alberta. Their research unknowingly led to a groundbreaking discovery in ophthalmic care having discovered a new method for treating vitreoretinal eye conditions with this laser technology. Over the years, ophthalmologists and retinal surgeons have expressed a keen interest in the potential application of femtosecond laser technology beyond its use in LASIK and cataract surgeries, such as for diabetic retinopathy and eye floaters. This enthusiasm stems from the remarkable abilities and precision of the technology.
Continue reading the article by INOVAIT